Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are evaluating the efficacy and safety of THB335 in adults with chronic spontaneous urticaria CSU who continue to experience hives and itching despite treatment with a second-generation H1 antihistamine. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare two doses of THB335 against a placebo. The study is designed for adults aged 18 to 85 who remain symptomatic despite standard care. Participants will be randomly assigned to receive either a higher dose or a lower dose of THB335, or a matching placebo, taken orally once daily for 12 weeks. All participants will continue their stable antihistamine treatment during this period. The study includes a Screening Period of up to 4 weeks before treatment, followed by a 12-week Treatment Period, and then a 4-week Follow-Up Period. During the trial, participants will complete daily electronic diaries to track symptoms such as hives and itching, and attend scheduled study visits for assessments. Researchers will measure changes in weekly Urticaria Activity Score UAS7 and other related scores from baseline to Week 12. Safety will be monitored through the recording of adverse events, vital signs, and laboratory tests up to Week 16. Overall, the total participation time is approximately 20 weeks.
Actively Recruiting
Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for adults with chronic spontaneous urticaria CSU that is not well controlled by antihistamines. CSU causes itchy hives and swelling beneath the skin without a clear cause. This phase 2 study compares two doses of ritlecitinib, 50 mg and 100 mg once daily, against a placebo in adults diagnosed with CSU for at least three months. Participants will be randomly assigned to receive either 50 mg or 100 mg of ritlecitinib or a placebo daily for 12 weeks Period A. After this, those on ritlecitinib continue their dose for another 12 weeks Period B, while those on placebo switch to 100 mg of ritlecitinib. The study will compare the effects and safety of these treatments over the two 12-week periods. During about 8 months of participation, individuals will make up to 9 visits to the study site for various tests including physical exams, hearing tests, blood tests, X-rays, and ECGs. They will also complete daily electronic diaries about their urticaria symptoms. Researchers will measure changes in symptom scores and monitor any side effects throughout the study to assess safety and treatment effects.
Actively Recruiting
Researchers are evaluating the safety and effects of tilrekimig, a study medicine being tested for severe asthma. The trial focuses on people who have had severe asthma for at least 12 months and experienced two or more asthma attacks in the past year. This phase 3 study aims to understand how tilrekimig compares to placebo shots in improving asthma symptoms and reducing attack rates. Participants will receive either tilrekimig or a placebo through subcutaneous injections administered at the study clinic. The study uses a randomized, double-blind design with parallel groups to compare outcomes. Treatment and observation take place over a 52-week period, with additional monitoring of safety up to 64 weeks. During the study, participants will have regular assessments including lung function tests, symptom questionnaires, and monitoring for asthma exacerbations and safety events. Researchers will measure the annual rate of asthma attacks, lung function changes, quality of life, and other asthma control indicators. The total duration for participant involvement is up to 64 weeks, including follow-up for adverse events.
Actively Recruiting
Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.
Actively Recruiting
Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.
Actively Recruiting
Researchers are evaluating WIN378, an ultra-long-acting medicine, in adults with moderate to severe asthma to assess its safety, how the body processes it, and its effects on lung function and asthma control. This global Phase 2 study has two parts Part A focuses on finding the right dose of WIN378, while Part B tests the chosen doses against placebo in adults with severe uncontrolled asthma to evaluate reduction in asthma flare-ups and improvements in quality of life. Participants receive WIN378 or placebo via subcutaneous injections. Part A tests three doses to understand pharmacokinetics, safety, and efficacy, including markers of inflammation in breath and blood, lung function, and asthma control. An interim analysis selects two doses for Part B, which compares these doses against placebo over 24 weeks to assess the annualized asthma exacerbation rate, lung function improvements, asthma control, and safety. During the study, participants undergo regular assessments including lung function tests, blood and breath tests for inflammation, questionnaires on asthma symptoms and quality of life, and monitoring for adverse events. Researchers track drug levels in the body and immune responses over about 60 weeks in Part A and 24 weeks after last dose in Part B. The total participation duration extends up to nearly five years, with continuous safety and efficacy monitoring.